Tim Wilsdon Presents Overview of Emerging Payment Models for Multi-Tumor Oncology Therapies at ISPOR Warsaw 2019 Conference

Tim Wilsdon Presents Overview of Emerging Payment Models for Multi-Tumor Oncology Therapies at ISPOR Warsaw 2019 Conference

March 22, 2019

Tim Wilsdon, vice president in the Life Sciences Practice at CRA, will present an overview of the impact of emerging payment models for oncology therapies that target multiple indications in an educational symposium at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place March 27-28, 2019 in Warsaw, Poland. The review will provide new insights about the risks and benefits that new pricing models can present to drug developers and health systems and how they can work to address challenges in market access and reimbursement.

“As more promising oncology therapies reach later stage development, industry stakeholders including pharma companies, payers, and government agencies are challenged to ensure patient access and budget predictability, especially in cases where therapies target multiple tumor types,” said Mr. Wilsdon. “Our presentation at ISPOR Warsaw 2019 will outline some of the innovative pricing models including managed entry agreements that can help reduce risk for drug developers and payers.”

Mr. Wilsdon will present during an educational symposium at the ISPOR Warsaw 2019 conference:

Title: Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements

Date: Wednesday, March 27, 2019

Time: 3:30-4:30 pm CET

For more information on this event, click here